Page 696 - Read Online

Fung et al. Hepatoma Res 2018;4:62 I http://dx.doi.org/10.20517/2394-5079.2018.92 Page 9 of 12

A 0.5

Cumulative rate of HCC recurrence 0.3 HBsAg ≥ 0.0005 IU/mL
0.4

0.2
P = 0.006

0.1
HBsAg < 0.0005 IU/mL
0.0
0 12 24 36
Number of patients Time after liver transplantation (months)
at risk
HBsAg ≥ 0.0005 IU/mL 21 19 17 15
HBsAg < 0.0005 IU/mL 33 33 32 31

B 0.5

0.4
Cumulative rate of HCC recurrence 0.3 HBsAg ≥ 0.0005 IU/mL

0.2
P = 0.006

0.1
HBsAg < 0.0005 IU/mL
0.0
0 12 24 36
Number of patients Time after liver transplantation (months)
at risk
HBsAg ≥ 0.0005 IU/mL 26 23 21 19
HBsAg < 0.0005 IU/mL 34 34 33 32

C 0.5

Cumulative rate of HCC recurrence 0.4 HBsAg ≥ 0.0005 IU/mL

0.3

0.2

P = 0.162
0.1

0.0 HBsAg < 0.0005 IU/mL
0 12 24 36
Number of patients
at risk Time after liver transplantation (months)
HBsAg ≥ 0.0005 IU/mL 27 25 23 21
HBsAg < 0.0005 IU/mL 25 24 23 22
Figure 4. A: Cumulative incidence of hepatocellular carcinoma recurrence according to hs-HBsAg level at 3 months after liver
transplantation; B: cumulative incidence of hepatocellular carcinoma recurrence according to hs-HBsAg level at 6 months after liver
transplantation; C: cumulative incidence of hepatocellular carcinoma recurrence according to hs-HBsAg level at 1 month after liver
transplantation